The most important thing is that in prostate cancer (PCa) TRPV6 channel is absent in healthy prostate while its expression appears de novo and correlates with the prostate malignancy [8, 16, 17], making it a prospective therapeutic target for the treatment of PCa. This evidence concerns the gene TRPV6 and prostate cancer.